Business
-
MannKind Corporation has filed a notice with the US Securities and Exchange Commission (SEC) stating that manufacturing of clinical trial supplies for its planned Phase 2/3 study of MNKD-101 clofazimine inhalation suspension in patients with… Read more . . .
-
Liquidia Corporation will pay Pharmosa Biopharm $10 million up front plus development and sales milestones worth up to $215 million and royalties on potential sales for North American development and commercialization rights to Pharmosa’s L606 liposomal… Read more . . .
-
Orion Pharmaceuticals has announced plans for a €30 million expansion of its production facility in Espoo, Finland, including a new filling line for its Easyhaler dry powder inhalers. The company said that it is responding… Read more . . .
-
According to TFF Pharmaceuticals, the company has received a 3-year Direct to Phase 2 Small Business Innovation Research (SBIR) grant worth ~$2.97 million from the National Institute of Allergy and Infectious Diseases (NIAID) for further… Read more . . .
-
Tonix Pharmaceuticals announced that it will acquire the US rights to Tosymra sumatriptan nasal spray from Upsher-Smith along with Zembrace SymTouch sumatriptan injection, both for the treatment of migraines. Dr. Reddy’s subsidiary Promius Pharma submitted… Read more . . .
-
Virpax Pharmaceuticals said that it has signed a cooperative research and development agreement (CRADA) for evaluation of the company’s NobrXiol (VRP324) cannabidiol nasal powder in rodent models of epilepsy and seizures by the Epilepsy Therapy Screening… Read more . . .
-
Padagis announced two recent ANDA submissions, including an ANDA for a generic version of Hikma’s Kloxxado naloxone nasal spray for the reversal of opioid overdose. Kloxxado, which delivers an 8 mg dose of naloxone compared… Read more . . .
-
Soft mist inhaler developer Resyca, a joint venture of Medspray Pharma and Recipharm, has announced the promotion of current Head of Development and Project Management Nicolas Buchmann to Chief Technical Officer. Buchman will take over… Read more . . .
-
Acadia Pharmaceuticals announced that it will develop ACP-101 (formerly LV-101) intranasal carbetocin for the treatment of excessive hunger in Prader-Willi syndrome (PWS). Acadia acquired the rights to the nasal spray when it acquired Levo Therapeutics… Read more . . .
-
Moat Biotechnology (MoatBio), a spin-out from Tetherex Pharmaceuticals, announced that it has closed a funding round of more than $6.5 million following an initial funding led by Cortado Ventures in September 2022. The company says that it… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal